{
  "title": "M21-1, Part V, Subpart iii, Chapter 8, Section A - Disabilities of the Gynecological System",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nFemale Sexual Arousal Disorder (FSAD)\n2\nOther Gynecological Disorders\n1\n.\nFemale Sexual Arousal Disorder (FSAD)\nIntroduction\nThis topic contains information about evaluating FSAD, including\ndefinition of FSAD\nrequesting examinations for FSAD claims\nwithin scope determinations for FSAD\nevaluating FSAD\n, and\nconsidering special monthly compensation (SMC) associated with FSAD\n.\nChange Date\nMay 19, 2020\nV.iii.8.A.1.a\n.\nDefinition:  FSAD\nFemale Sexual Arousal Disorder (FSAD)\nrefers to the continual or recurrent physical inability of a woman to accomplish or maintain an ample lubrication-swelling reaction during sexual intercourse.  Decreased blood flow to the genital area is believed to contribute to FSAD similar to the role of vascular disease in male erectile dysfunction.  Other causes may include nerve and/or tissue damage.\nImportant\n:\nFSAD is a physical disorder characterized by physiological findings/damage to the gynecological system.  It is\nnot\na psychiatric condition found in the Diagnostic and Statistical Manual, fifth version (DSM-5) for mental disorders.  DSM-5 does include a diagnosis of female sexual interest/arousal disorder, which is a different disorder and is not synonymous with FSAD.\nA diagnosis of FSAD\ncannot\nbe rendered or confirmed by a mental health examiner.  When a mental health examination or mental health treatment records suggest a diagnosis of FSAD, including FSAD secondary to medication for a psychiatric disorder, the diagnosis must be confirmed in other medical evidence by a qualified medical professional.\nV.iii.8.A.1.b\n.\nRequesting Examinations for FSAD Claims\nThe\nGynecological Conditions Disability Benefits Questionnaire\n(DBQ) is the appropriate DBQ to order when a Department of Veterans Affairs examination is necessary to assist in substantiating a claim of FSAD or other female sexual dysfunction.\nNotes\n:\nIf the Veteran claims service connection (SC) for FSAD or other sexual dysfunction and the exam threshold described in\n38 CFR 3.159(c)(4)\nis met, request the examination using the\nGynecological Conditions\nDisability Benefits Questionnaire\n.\nThe\nGynecological Conditions\nDisability Benefits Questionnaire\nincludes a specific section concerning FSAD that includes a request for the examiner to identify whether\nthe Veteran has FSAD, and\nFSAD, if present, is at least as likely as not attributable to another condition.\nIn all cases, if an examiner diagnoses FSAD, the\nGynecological Conditions Disability Benefits Questionnaire\nmust be completed, or sufficient alternative evidence (such as private medical evidence submitted in lieu of an examination) must be of record.\nWhen a claimed gynecological issue is examined using an examination other than the\nGynecological Conditions Disability Benefits Questionnaire\n, such as an examination of scars following cesarean section using the\nScars/Disfigurement Disability Benefits Questionnaire\n, also request the\nGynecological Conditions Disability Benefits Questionnaire\nto evaluate the underlying gynecological issue, including FSAD.\nV.iii.8.A.1.c\n.\nWithin Scope Determinations for FSAD\nIf SC for FSAD is not expressly claimed, consider FSAD within scope of the claim in the circumstances described in the table below.\nWhen ...\nThen consider FSAD within scope of the ...\nthe\nGynecological Conditions Disability Benefits Questionnaire\nindicates that FSAD is attributable to the claimed gynecological disorder\nclaimed gynecological disorder.\nNote\n:  When a gynecological disorder is claimed, the examiner must address whether FSAD is present and if it is related to the claimed gynecological disorder as noted in\nM21-1, Part V, Subpart iii, 8.A.1.b\n.\na mental health examination indicates a diagnosis of FSAD is present and provides possible nexus information linking it to medication or treatment for a mental health disorder\nclaimed mental health condition.\nNote\n:  The diagnosis of FSAD must be confirmed by an appropriate non-mental health examiner.  Analyze the evidence of record to determine whether the criteria under\n38 CFR 3.159(c)(4)\nare satisfied to request further examination of FSAD.\nother evidence submitted with the claim leads to a within scope determination for FSAD as described at\nM21-1, Part V, Subpart ii, 3.A.2.c\nclaimed condition.\nV.iii.8.A.1.d\n.\nEvaluating FSAD\nWhen the requirements are met, SC for FSAD will be awarded as a stand-alone gynecological disability using\n38 CFR 4.116, diagnostic code (DC) 7632\nwith a 0-percent evaluation.  This is the maximum evaluation available for FSAD.\nNote\n:  The original clarification that FSAD is a disorder subject to SC was not a regulatory change.  Consequently, the provisions of\n38 CFR 3.114\ndo not apply for assignment of the effective date.  Subsequent updates to\n38 CFR 4.116\n, including the addition of DC 7632 for FSAD, effective May 13, 2018, are, similarly, not liberalizing.\nV.iii.8.A.1.e\n.\nConsidering SMC Associated With FSAD\nEntitlement to SMC (k) for loss of use of a creative organ will be inferred and awarded whenever SC for FSAD is granted.\nNote\n:  If SC was previously established for FSAD but SMC was not awarded, place entitlement to SMC at issue and grant.  The effective date for the award of SMC will be the date SC for FSAD was established.\n2\n.\nOther Gynecological Disorders\nIntroduction\nThis topic contains information about evaluating other gynecological disorders, including\nSC for disorders of menstruation\nevaluating pelvic organ prolapse\nmalignant neoplasms of the gynecological system\ndisfigurement due to benign or malignant neoplasms\ncervical dysplasia\nhuman papillomavirus (HPV)\n, and\nchanges in the rating schedule for gynecological conditions and disorders of the breast\n.\nChange Date\nNovember 8, 2021\nV.iii.8.A.2.a\n.\nSC for Disorders of Menstruation\nA disease or injury resulting in ovarian dysfunction affecting the menstrual cycle, such as dysmenorrhea and secondary amenorrhea, can be service-connected (SC).  Evaluate using\n38 CFR 4.116, DC 7615\n.\nNotes\n:\nSC cannot be established for primary amenorrhea or dysmenorrhea.  By definition, neither disorder would be incurred in or aggravated by service.\nSC can be established for secondary amenorrhea or dysmenorrhea when the evidence shows that they are due to an ovarian disability or any other female reproductive organ disorder or other SC disability.\nV.iii.8.A.2.b\n.\nEvaluating Pelvic Organ Prolapse\nApply the principles below to evaluate pelvic organ prolapse.\nDo not assign multiple evaluations under\n38 CFR 4.116, DC 7621\nfor prolapse of multiple pelvic organs.\nWhen prolapse is incomplete or complete, assign a 10-percent evaluation.  In addition, evaluate residual disabilities or symptoms under the corresponding DC and combine, as usual, under\n38 CFR 4.25\n.\nExample\n:  SC is warranted for pelvic organ prolapse.  Examination shows that, as a result of complete prolapse, the Veteran also experiences urinary incontinence requiring the wearing of absorbent materials that must be changed twice daily, impairment of sphincter control resulting in slight leakage, and localized dermatitis affecting less than five percent of body area that is treated with topical therapy.  The following evaluations will be established for the pelvic organ prolapse and residuals:\n38 CFR 4.116, DC 7621\n, 10%, pelvic organ prolapse\n38 CFR 4.115b, DC 7517\n, 20%, urinary incontinence due to pelvic organ prolapse\n38 CFR 4.114, DC 7332\n, 10%, impairment of sphincter control due to pelvic organ prolapse,\nand\n38 CFR 4.118, DC 7806\n, 0%, dermatitis due to pelvic organ prolapse.\nNote\n:  Prior to the changes to\n38 CFR 4.116\n, effective May 13, 2018, these conditions were evaluated under\n38 CFR 4.116, DC 7621 to 7623\n.\nReferences\n:  For more information on\neffective dates for decisions impacted by regulatory changes, see\nM21-1, Part V, Subpart ii, 4.A.6\n, and\nprotection of evaluations based on a change in diagnostic criteria, see\nM21-1, Part X, Subpart ii, 1.B.4\n.\nV.iii.8.A.2.c\n.\nMalignant Neoplasms of the Gynecological System\nSeparate 100-percent evaluations will be assigned for both active gynecological cancer and active breast cancer.  Metastasis of a gynecological cancer or breast cancer to a different body system will also be evaluated separately.\nConsider corresponding entitlement to SMC.\nReferences\n:  For more information on\ntemporary total evaluations for cancers, see\nM21-1, Part VIII, Subpart iv, 8.D.3.e\nevaluating malignant neoplasms and associated impairments, see\nM21-1, Part V, Subpart ii, 3.D.5.a and b\n, and\nentitlement to SMC (k) for anatomical loss of a creative organ, see\n38 CFR 3.350(a)\n, and\nM21-1, Part VIII, Subpart iv, 4.A.4.d\n.\nV.iii.8.A.2.d\n.\nDisfigurement Due to Benign or Malignant Neoplasms\nDo not evaluate disfigurement due to benign or malignant neoplasms of the gynecological system analogous to\n38 CFR 4.118, DC 7800\n.  DC 7800 is for evaluation of disfigurement of the head, face, or neck only.\nV.iii.8.A.2.e\n.\nCervical Dysplasia\nDo not routinely award SC for cervical dysplasia, also referred to as cervical intraepithelial neoplasia (CIN).  Cervical dysplasia/CIN is not a disease or injury.  It is a cellular abnormality of the cervix revealed by Papanicolaou (Pap) smear testing that generally resolves without treatment or residuals.  In these cases, there is an abnormal laboratory finding but no disability, and SC is not warranted.\nSC may be warranted if cervical dysplasia/CIN\nrequires treatment that leaves residuals, or\nis linked to the subsequent development of cervical cancer.\nUse the table below to determine the appropriate actions to take when SC is claimed following an in-service confirmed finding of cervical dysplasia/CIN.\nIf medical evidence shows the subsequent development of …\nThen award SC for …\nAdditional Information to Consider\nchronic or severe dysplasia/CIN requiring treatment,\nand\nchronic residuals of the required treatment\nresiduals of cervical dysplasia/CIN.\nCommon procedures for treatment of chronic or severe dysplasia/CIN include\ncauterization\nlaser surgery\ncryosurgery, or\nloop electrosurgical excision procedure (LEEP).\ncervical cancer,\nand\na link between the in-service dysplasia/CIN and the cancer\ncervical cancer and/or residuals.\nIn-service cervical dysplasia that resolved without residuals is less likely to be related to later-developing cervical cancer.  However, these cases require a medical opinion to determine whether a relationship exists between the conditions.\nNote\n:  Cervical dysplasia is often associated with human papillomavirus (HPV) infection.  There are over 60 types of HPV infection, and only certain types are associated with high-grade cervical dysplasia and cancer.\nV.iii.8.A.2.f\n.\nHPV\nDo not routinely award SC for HPV infection.  Usually, HPV infections are asymptomatic and identified only as a finding on a Pap smear.  Most resolve spontaneously without residuals requiring only periodic pap smears for follow-up.  In these cases, there is an abnormal laboratory finding but no disability, and SC is not warranted.\nSC may be warranted if a disability develops as a result of an in-service HPV infection.  Two circumstances that may warrant SC are\ngenital warts that are shown in service or by nexus to be associated with the HPV infection, and\nHPV resulting in persistent infection that progresses to cervical dysplasia and subsequently to cervical cancer.\nImportant\n:  A medical nexus is required to establish an association between genital warts and in-service HPV infection or between cervical cancer and in-service HPV infection.\nNote\n:  There are multiple varieties of HPV infection which can cause common warts, plantar warts, and other findings.  HPV is not limited to sexual transmission.\nReferences\n:  For more information on considering claims for SC associated with sexually transmitted diseases, see\n38 CFR 3.301(c)(1)\n, and\nM21-1, Part V, Subpart iii, 7.5.a\n.\nV.iii.8.A.2.g\n.\nChanges in the Rating Schedule for Gynecological Conditions and Disorders of the Breast\nThe rating criteria for gynecological conditions and disorders of the breast have undergone historical changes.  Recent full-scale historical revisions were effective on the following dates:\nMay 13, 2018, and\nMay 22, 1995.\nNote\n:  These changes in the rating criteria\nare not considered liberalizing, and\nshould not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 11px\"><a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">&lt;-- Previous Section</a> <a articleid=\"554400000180879\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section B - Disabilities of the Breast\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Section</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This section contains the following topics:</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 500px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 423px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1 </span></span></div></td><td style=\"width: 423px; vertical-align: middle; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\">Female Sexual Arousal Disorder (FSAD)</span></a></span></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 423px; vertical-align: middle; padding: 1px;\"><div><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Other Gynecological Disorders</span></span></a></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">       </span></span></p></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Female Sexual Arousal Disorder (FSAD)</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><div></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about evaluating FSAD, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\">definition of FSAD</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1b\" target=\"_self\">requesting examinations for FSAD claims</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1c\" target=\"_self\">within scope determinations for FSAD</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1d\" target=\"_self\">evaluating FSAD</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1e\" target=\"_self\">considering special monthly compensation (SMC) associated with FSAD</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May 19, 2020</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.1.a<a id=\"1a\" name=\"1a\">.</a> Definition:  FSAD</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Female Sexual Arousal Disorder (FSAD)</em></strong> <span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">refers to the continual or recurrent physical inability of a woman to accomplish or maintain an ample lubrication-swelling reaction during sexual intercourse.  Decreased blood flow to the genital area is believed to contribute to FSAD similar to the role of vascular disease in male erectile dysfunction.  Other causes may include nerve and/or tissue damage.</span></span></span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>: </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">FSAD is a physical disorder characterized by physiological findings/damage to the gynecological system.  It is <strong><em>not</em></strong> a psychiatric condition found in the Diagnostic and Statistical Manual, fifth version (DSM-5) for mental disorders.  DSM-5 does include a diagnosis of female sexual interest/arousal disorder, which is a different disorder and is not synonymous with FSAD.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A diagnosis of FSAD <strong><em>cannot</em></strong> be rendered or confirmed by a mental health examiner.  When a mental health examination or mental health treatment records suggest a diagnosis of FSAD, including FSAD secondary to medication for a psychiatric disorder, the diagnosis must be confirmed in other medical evidence by a qualified medical professional. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.1.b<a id=\"1b\" name=\"1b\">.</a> Requesting Examinations for FSAD Claims</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The <em>Gynecological Conditions Disability Benefits Questionnaire</em> (DBQ) is the appropriate DBQ to order when a Department of Veterans Affairs examination is necessary to assist in substantiating a claim of FSAD or other female sexual dysfunction. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the Veteran claims service connection (SC) for FSAD or other sexual dysfunction and the exam threshold described in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=53b7538e3271abcd838e0d5d233834c7&amp;mc=true&amp;node=se38.1.3_1159&amp;rgn=div8\" target=\"_blank\">38 CFR 3.159(c)(4)</a> is met, request the examination using the <em>Gynecological Conditions </em><em>Disability Benefits Questionnaire</em>.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The <em>Gynecological Conditions </em><em>Disability Benefits Questionnaire</em> includes a specific section concerning FSAD that includes a request for the examiner to identify whether</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the Veteran has FSAD, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">FSAD, if present, is at least as likely as not attributable to another condition.</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In all cases, if an examiner diagnoses FSAD, the <em>Gynecological Conditions Disability Benefits Questionnaire</em> must be completed, or sufficient alternative evidence (such as private medical evidence submitted in lieu of an examination) must be of record.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When a claimed gynecological issue is examined using an examination other than the <em>Gynecological Conditions Disability Benefits Questionnaire</em>, such as an examination of scars following cesarean section using the <em>Scars/Disfigurement Disability Benefits Questionnaire</em>, also request the <em>Gynecological Conditions Disability Benefits Questionnaire</em> to evaluate the underlying gynecological issue, including FSAD.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.1.c<a id=\"1c\" name=\"1c\">.</a>  Within Scope Determinations for FSAD</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If SC for FSAD is not expressly claimed, consider FSAD within scope of the claim in the circumstances described in the table below. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a When-Then table.  Column 1 provides the criteria and column 2 provides the actions to take.\" width=\"510\"><tbody><tr><td style=\"width: 246px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>When ...</strong></span></span></div></td><td style=\"width: 264px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Then consider FSAD within scope of the ...</strong></span></span></div></td></tr><tr><td style=\"width: 246px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the <em>Gynecological Conditions Disability Benefits Questionnaire</em> indicates that FSAD is attributable to the claimed gynecological disorder</span></span></div></td><td style=\"width: 264px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">claimed gynecological disorder. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  When a gynecological disorder is claimed, the examiner must address whether FSAD is present and if it is related to the claimed gynecological disorder as noted in <a href=\"#1b\" target=\"_self\">M21-1, Part V, Subpart iii, 8.A.1.b</a>.</span></span></div></td></tr><tr><td style=\"width: 246px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">a mental health examination indicates a diagnosis of FSAD is present and provides possible nexus information linking it to medication or treatment for a mental health disorder</span></span></div></td><td style=\"width: 264px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">claimed mental health condition.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  The diagnosis of FSAD must be confirmed by an appropriate non-mental health examiner.  Analyze the evidence of record to determine whether the criteria under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=c0d6c78169a7dedfff398785df1a2da4&amp;mc=true&amp;node=se38.1.3_1159&amp;rgn=div8\" target=\"_blank\">38 CFR 3.159(c)(4)</a> are satisfied to request further examination of FSAD.</span></span></div></td></tr><tr><td style=\"width: 246px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">other evidence submitted with the claim leads to a within scope determination for FSAD as described at <a articleid=\"554400000180486\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section A - Determining the Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180486/M21-1-Part-V-Subpart-ii-Chapter-3-Section-A-Determining-the-Issues\">M21-1, Part V, Subpart ii, 3.A.2.c</a></span></span></div></td><td style=\"width: 264px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">claimed condition.</span></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.1.d<a id=\"1d\" name=\"1d\">.</a> Evaluating FSAD </span></span></h3><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When the requirements are met, SC for FSAD will be awarded as a stand-alone gynecological disability using <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, diagnostic code (DC) 7632</a> with a 0-percent evaluation.  This is the maximum evaluation available for FSAD.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  The original clarification that FSAD is a disorder subject to SC was not a regulatory change.  Consequently, the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=bb790b7db78d279bd670911757fb42af&amp;mc=true&amp;node=se38.1.3_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 3.114</a> do not apply for assignment of the effective date.  Subsequent updates to <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116</a>, including the addition of DC 7632 for FSAD, effective May 13, 2018, are, similarly, not liberalizing. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.8.A.1.e<a id=\"1e\" name=\"1e\">.</a>  Considering SMC Associated With FSAD</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Entitlement to SMC (k) for loss of use of a creative organ will be inferred and awarded whenever SC for FSAD is granted.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><strong>Note</strong></em>:  If SC was previously established for FSAD but SMC was not awarded, place entitlement to SMC at issue and grant.  The effective date for the award of SMC will be the date SC for FSAD was established.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"></h2><p class=\"ng-scope\"></p><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Other Gynecological Disorders</span></span></h2><p class=\"ng-scope\"> <br/><br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><div></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about evaluating other gynecological disorders, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2a\" target=\"_self\">SC for disorders of menstruation</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2b\" target=\"_self\">evaluating pelvic organ prolapse</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2c\" target=\"_self\">malignant neoplasms of the gynecological system</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2d\" target=\"_self\">disfigurement due to benign or malignant neoplasms</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2e\" target=\"_self\">cervical dysplasia</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2f\" target=\"_self\">human papillomavirus (HPV)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2g\" target=\"_self\">changes in the rating schedule for gynecological conditions and disorders of the breast</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 8, 2021</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.8.A.2.a<a id=\"2a\" name=\"2a\">.</a>  SC for Disorders of Menstruation</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A disease or injury resulting in ovarian dysfunction affecting the menstrual cycle, such as dysmenorrhea and secondary amenorrhea, can be service-connected (SC).  Evaluate using <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7615</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>:  </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC cannot be established for primary amenorrhea or dysmenorrhea.  By definition, neither disorder would be incurred in or aggravated by service. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC can be established for secondary amenorrhea or dysmenorrhea when the evidence shows that they are due to an ovarian disability or any other female reproductive organ disorder or other SC disability. </span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.8.A.2.b<a name=\"2b\">.</a>  Evaluating Pelvic Organ Prolapse</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Apply the principles below to evaluate pelvic organ prolapse.<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do not assign multiple evaluations under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7621</a> for prolapse of multiple pelvic organs.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When prolapse is incomplete or complete, assign a 10-percent evaluation.  In addition, evaluate residual disabilities or symptoms under the corresponding DC and combine, as usual, under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_125&amp;rgn=div8\" target=\"_blank\">38 CFR 4.25</a>.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>:  SC is warranted for pelvic organ prolapse.  Examination shows that, as a result of complete prolapse, the Veteran also experiences urinary incontinence requiring the wearing of absorbent materials that must be changed twice daily, impairment of sphincter control resulting in slight leakage, and localized dermatitis affecting less than five percent of body area that is treated with topical therapy.  The following evaluations will be established for the pelvic organ prolapse and residuals:</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7621</a>, 10%, pelvic organ prolapse</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=cee00fac612370cd96f1d822b36262da&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7517</a>, 20%, urinary incontinence due to pelvic organ prolapse</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=5f8ec3f4e11f71d06e41b855977bb7fb&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7332</a>, 10%, impairment of sphincter control due to pelvic organ prolapse, <strong><em>and</em></strong></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=5f8ec3f4e11f71d06e41b855977bb7fb&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7806</a>, 0%, dermatitis due to pelvic organ prolapse.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Prior to the changes to <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116</a>, effective May 13, 2018, these conditions were evaluated under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7621 to 7623</a>. </span></span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">effective dates for decisions impacted by regulatory changes, see <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.6</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">protection of evaluations based on a change in diagnostic criteria, see <a articleid=\"554400000177962\" articlename=\"M21-1, Part X, Subpart ii, Chapter 1, Section B - Protected Ratings\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177962/M21-1-Part-X-Subpart-ii-Chapter-1-Section-B-Protected-Ratings\">M21-1, Part X, Subpart ii, 1.B.4</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.2.c<a id=\"2c\" name=\"2c\">.</a>  Malignant Neoplasms of the Gynecological System</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Separate 100-percent evaluations will be assigned for both active gynecological cancer and active breast cancer.  Metastasis of a gynecological cancer or breast cancer to a different body system will also be evaluated separately. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Consider corresponding entitlement to SMC. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">temporary total evaluations for cancers, see <a articleid=\"554400000177543\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section D - Other Temporary Total Evaluations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177543/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-D-Other-Temporary-Total-Evaluations\">M21-1, Part VIII, Subpart iv, 8.D.3.e</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating malignant neoplasms and associated impairments, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.5.a and b</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">entitlement to SMC (k) for anatomical loss of a creative organ, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=546be1e864685b4584786ea651ec7827&amp;mc=true&amp;node=se38.1.3_1350&amp;rgn=div8\" target=\"_blank\">38 CFR 3.350(a)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4.d</a>.  </span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.2.d<a id=\"2d\" name=\"2d\">.</a>  Disfigurement Due to Benign or Malignant Neoplasms </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do not evaluate disfigurement due to benign or malignant neoplasms of the gynecological system analogous to <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=68490608d79a4870dab0180df9f932af&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a>.  DC 7800 is for evaluation of disfigurement of the head, face, or neck only.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.2.e<a id=\"2e\" name=\"2e\">.</a> Cervical Dysplasia</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do not routinely award SC for cervical dysplasia, also referred to as cervical intraepithelial neoplasia (CIN).  Cervical dysplasia/CIN is not a disease or injury.  It is a cellular abnormality of the cervix revealed by Papanicolaou (Pap) smear testing that generally resolves without treatment or residuals.  In these cases, there is an abnormal laboratory finding but no disability, and SC is not warranted. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC may be warranted if cervical dysplasia/CIN</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">requires treatment that leaves residuals, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">is linked to the subsequent development of cervical cancer. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Use the table below to determine the appropriate actions to take when SC is claimed following an in-service confirmed finding of cervical dysplasia/CIN.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is an if-then-additional information table.  Column 1 provides the criteria,  column 2 provides instructions to determine the appropriate actions to take when SC is claimed following an in-service confirmed finding of cervical dysplasia/CIN, and column 3 provides additional information to consider.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>If medical evidence shows the subsequent development of …</strong></span></span></div></th><th scope=\"col\" style=\"width: 162px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Then award SC for …</strong></span></span></div></th><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Additional Information to Consider</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">chronic or severe dysplasia/CIN requiring treatment, <em>and</em></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">chronic residuals of the required treatment</span></span></div></li></ul></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">residuals of cervical dysplasia/CIN.</span></span></div></td><td style=\"width: 174px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Common procedures for treatment of chronic or severe dysplasia/CIN include</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cauterization</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">laser surgery</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cryosurgery, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">loop electrosurgical excision procedure (LEEP).</span></span></div></li></ul></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cervical cancer, <em>and</em></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">a link between the in-service dysplasia/CIN and the cancer</span></span></div></li></ul></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cervical cancer and/or residuals.</span></span></div></td><td style=\"width: 174px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In-service cervical dysplasia that resolved without residuals is less likely to be related to later-developing cervical cancer.  However, these cases require a medical opinion to determine whether a relationship exists between the conditions.</span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Cervical dysplasia is often associated with human papillomavirus (HPV) infection.  There are over 60 types of HPV infection, and only certain types are associated with high-grade cervical dysplasia and cancer. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.A.2.f<a id=\"2f\" name=\"2f\">.</a>  HPV</span></span></h3><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Do not routinely award SC for HPV infection.  Usually, HPV infections are asymptomatic and identified only as a finding on a Pap smear.  Most resolve spontaneously without residuals requiring only periodic pap smears for follow-up.  In these cases, there is an abnormal laboratory finding but no disability, and SC is not warranted. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC may be warranted if a disability develops as a result of an in-service HPV infection.  Two circumstances that may warrant SC are</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">genital warts that are shown in service or by nexus to be associated with the HPV infection, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HPV resulting in persistent infection that progresses to cervical dysplasia and subsequently to cervical cancer.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  A medical nexus is required to establish an association between genital warts and in-service HPV infection or between cervical cancer and in-service HPV infection. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  There are multiple varieties of HPV infection which can cause common warts, plantar warts, and other findings.  HPV is not limited to sexual transmission.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on considering claims for SC associated with sexually transmitted diseases, see </span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=53b7538e3271abcd838e0d5d233834c7&amp;mc=true&amp;node=se38.1.3_1301&amp;rgn=div8\" target=\"_blank\">38 CFR 3.301(c)(1)</a>, and</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">M21-1, Part V, Subpart iii, 7.5.a</a>.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.8.A.2.g<a id=\"2g\" name=\"2g\">.</a>  Changes in the Rating Schedule for Gynecological Conditions and Disorders of the Breast</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The rating criteria for gynecological conditions and disorders of the breast have undergone historical changes.  Recent full-scale historical revisions were effective on the following dates:</span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May 13, 2018, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May 22, 1995.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  These changes in the rating criteria</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">are not considered liberalizing, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">should not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 11px\"><a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">&lt;-- Previous Section</a> <a articleid=\"554400000180879\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section B - Disabilities of the Breast\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&mc=true&node=se38.1.4_1116&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=53b7538e3271abcd838e0d5d233834c7&mc=true&node=se38.1.3_1159&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=bb790b7db78d279bd670911757fb42af&mc=true&node=se38.1.3_1114&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&mc=true&node=se38.1.4_1116&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&mc=true&node=se38.1.4_125&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=53b7538e3271abcd838e0d5d233834c7&mc=true&node=se38.1.3_1301&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=546be1e864685b4584786ea651ec7827&mc=true&node=se38.1.3_1350&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=5f8ec3f4e11f71d06e41b855977bb7fb&mc=true&node=se38.1.4_1114&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=5f8ec3f4e11f71d06e41b855977bb7fb&mc=true&node=se38.1.4_1118&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=68490608d79a4870dab0180df9f932af&mc=true&node=se38.1.4_1118&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=c0d6c78169a7dedfff398785df1a2da4&mc=true&node=se38.1.3_1159&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=cee00fac612370cd96f1d822b36262da&mc=true&node=se38.1.4_1115b&rgn=div8"
  ],
  "scraped_at": "2025-06-16T22:45:16.761925",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast"
}